Humoral hypercalcaemia of malignancy: metabolic and histomorphometric studies during surgical management of the primary tumour
- PMID: 3016790
Humoral hypercalcaemia of malignancy: metabolic and histomorphometric studies during surgical management of the primary tumour
Abstract
Several aspects of calcium metabolism were studied in five patients during the surgical exploration of malignant tumours associated with humorally-mediated hypercalcaemia. Before operation in all patients the renal tubular threshold for calcium reabsorption was raised and the threshold for renal tubular phosphate reabsorption depressed. On removal of the primary tumour in three cases, serum calcium returned to normal, renal calcium threshold fell, renal phosphate threshold rose, but urinary hydroxyproline excretion did not change. In two patients where the tumour proved inoperable, serum calcium remained elevated and no changes in renal calcium threshold or phosphate threshold occurred. Histomorphometry carried out on biopsy specimens from four patients showed normal bone resorption in three, and slightly increased resorption in one, without depression of osteoblastic bone formation. It is suggested that hypercalcaemia in these patients resulted mainly from an alteration in renal calcium threshold caused by a humoral substance released by tumour cells. Correction of hypercalcaemia on removal of the primary tumour was achieved rapidly and could be explained principally by a reduction in renal calcium threshold with increased loss of calcium into the urine. These data contrast with those of many previous studies which have emphasised the predominant role of accelerated osteoclastic bone resorption as the principal cause of hypercalcaemia in malignancy and suggest that a renal effect of the putative humoral agent may predominate in some cases.
Similar articles
-
Bone resorption and renal calcium reabsorption in renal cell carcinoma-bearing mice: the effects of bisphosphonate.BJU Int. 2007 Jun;99(6):1530-3. doi: 10.1111/j.1464-410X.2007.06862.x. Epub 2007 Apr 8. BJU Int. 2007. PMID: 17428243
-
Familial benign hypercalcaemia. Study of a large family.Q J Med. 1983 Spring;52(206):120-40. Q J Med. 1983. PMID: 6310672
-
Malignancy-associated hypercalcaemia: relationship between mechanisms of hypercalcaemia and response to antihypercalcaemic therapy.Bone Miner. 1987 May;2(3):227-42. Bone Miner. 1987. PMID: 2974309
-
The skeleton in primary hyperparathyroidism: a review focusing on bone remodeling, structure, mass, and fracture.APMIS Suppl. 2001;(102):1-52. APMIS Suppl. 2001. PMID: 11419022 Review.
-
Pathophysiology and management of severe hypercalcemia.Endocrinol Metab Clin North Am. 1993 Jun;22(2):343-62. Endocrinol Metab Clin North Am. 1993. PMID: 8325291 Review.
Cited by
-
Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.Drugs. 1991 Feb;41(2):289-318. doi: 10.2165/00003495-199141020-00009. Drugs. 1991. PMID: 1709854 Review.